We develop GPCR modulators for Idiopathic Pulmonary Fibrosis (IPF) and other inflammatory and metabolic conditions
ABOUT INNOSPERA PHARMA
Innospera Pharma is a privately held, clinical-stage biotech company developing small-molecule GPCR modulators for chronic and fibrotic diseases. Its lead candidate, ING-006, is a next-generation GPR84 modulator, that has demonstrated robust anti-fibrotic activity in gold-standard preclinical models.
Building on the clinical precedent established by earlier GPR84 modulators that have shown therapeutic potential in fibrotic and metabolic disorders, ING-006 combines a markedly improved pharmacological profile with an anticipated broad safety margin and favorable tolerability.
The Company’s pipeline includes additional GPCR modulators addressing cardiometabolic and other chronic conditions.
Leadership team
Board of Directors
Pierre Laurin, BPharm, MSc
Executive Chairman and co-founder, Innospera
François Ravenelle, PhD
President and CEO, Innospera
Lyne Gagnon, PhD
CSO and co-founder, Innospera
Patricia Escoffier, PhD
Principal, Seido Capital
Hélène Moore, MBA
Director, Anges Québec
Denis Garceau, BPharm, PhD
Ex-CSO, Bellus Health
Hubert Sibre, LLB
Partner, Miller Thomson
Maxime Daigle, CPA
Board Observer, Director, Investissement Québec
Our Science
Our scientists leverage decades of experience in developing small molecule GPCR modulators to address inflammatory-driven conditions that meet three criteria:
1
Target receptors drive the severity of the selected medical condition, the disease progression or low survival rates
2
Medical condition remains an unmet medical need and has a clear regulatory pathway
3
In gold standard preclinical models, our lead drug candidates appear superior to other products used today, or that are in development.
Fibrosis Reduction & Metabolic Regulation: A Balancing Act
Balance between GPR84 and GPR40 plays a significant role in the modulation of the fibrotic and metabolic processes.
Our library of small molecule modulators allows us to re-establish a more favorable GPR84 / GPR40 balance.
Our Lead Product: ING-006
THE IPF
OPPORTUNITY
Low life expectancy
3 to 5 years post diagnosis.
Dire unmet need
Standard of care products slow down IPF only.
Tolerability issues
Low 26.4% adoption rate due to GI adverse events.
3M adults affected worldwide
~140k in the US (rare disease).
OUR TARGET:
GPR84
Well-documented target
Vast preclinical and clinical data in inflammation and fibrosis.
Upregulated in IPF
GPR84 expression increases as a function of the severity of the disease.
ING-006 is a first-in-class GPR84 modulator
Differs from previous GPR84 antagonist programs.
SUPERIOR
DMPK
Rapid absorption/distribution
Lipid-mimetic design enables fast uptake and efficient distribution to lung tissue.
Cmax-driven pharmacodynamics
Allows low systemic burden and provides built-in safety and tolerability
Combination-ready candidate
Profile allows broad compatibility with other IPF products
An attractive product profile
A once-daily oral administration of an anticipated well-tolerated drug, with a differentiated MoA (first-in-class GPR84 modulator).
Combining efficacy with safety and tolerability
Unlike standards of care and most products in development that have important tolerability issues, we anticipate ING-006 will provide an efficacious treatment that preserves patients’ quality of life.
Our Pipeline
ING-008 and ING-Series: Expanding the Lipid-Mimetic Platform
Next-Generation Lipid-Mimetics
Analogues of prior clinical and preclinical fatty acid products, designed with differentiated GPCR modulation and unique DMPK properties.
Organ- and Indication-Specific Potential
Opportunity to target new tissues and diseases while maintaining the strong safety/tolerability profile of the class.
Pipeline Expansion
Multiple candidates under evaluation in cardiometabolic diseases, including obesity and MASH.